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Abstract
Immunology-based interventions have been proposed as a promising curative chance to effectively attack postoperative
minimal residual disease and distant metastatic localizations of prostate tumors. We developed a chimeric antigen receptor
(CAR) construct targeting the human prostate-specific membrane antigen (hPSMA), based on a novel and high affinity
specific mAb. As a transfer method, we employed last-generation lentiviral vectors (LV) carrying a synthetic bidirectional
promoter capable of robust and coordinated expression of the CAR molecule, and a bioluminescent reporter gene to allow
the tracking of transgenic T cells after in vivo adoptive transfer. Overall, we demonstrated that CAR-expressing LV efficiently
transduced short-term activated PBMC, which in turn were readily stimulated to produce cytokines and to exert a relevant
cytotoxic activity by engagement with PSMA+ prostate tumor cells. Upon in vivo transfer in tumor-bearing mice, CAR-
transduced T cells were capable to completely eradicate a disseminated neoplasia in the majority of treated animals, thus
supporting the translation of such approach in the clinical setting.
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Introduction
Adoptive cell therapy with unmodified and ex vivo expanded T
cells has proved effective against different tumor entities, in
particular melanoma and EBV-associated tumors [1]. Nowadays,
the genetic modification of T cells can confer new tumor-targeting
properties to naturally occurring lymphocytes, thus overcoming
the reliance on components of the endogenous immune system.
While transduction with Ag-specific TCR can only redirect T
cell activity based on the same recognition characteristics,
Chimeric Antigen Receptor (CAR) technology has the potentiality
to endow T cells with the advantageous features of an antibody,
namely specificity, affinity and the possibility to target non-protein
antigens [2]. Moreover, in an unique molecule CAR provides
some measures to counteract tumor immune evasion strategies: it
relieves T cell recognition and activity of MHC restriction and
expression, and can relay costimulatory signals through its
intracellular domains.
Therapeutic efficacy of CAR T cells have been already reported
in patients, in particular against chronic lymphocytic leukemia
(CLL) and acute lymphoblastic leukemia (ALL) [3–6] with very
promising results in terms of disease free survival and complete
hematological and molecular responses even in subjects who failed
all previous standard treatments. However, hematological malig-
nancies, in particular those of B cell origin, can be regarded as an
ideal target for immunotherapeutic approaches [7]. Indeed, these
malignant cells naturally provide costimulatory receptor ligands
and share the same physiological compartments with adoptively
transferred T cells. Finally, elimination of normal B cells is
associated with non life-threatening adverse effects, which can be
clinically managed with intravenous immunoglobulin administra-
tion.
Conversely, solid tumor treatment remains a major challenge
and should be improved both in terms of clinical efficacy and
safety. Partial successes were experienced against neuroblastoma
using GD2-specific CAR T cells without pre-conditioning
regimen, in the virtual absence of side effects [8,9]. By contrast,
no clinical responses were recorded with the infusion of T cells
redirected against the folate receptor in ovarian carcinoma
patients [10], nor against carboxy-anhydrase IX (CAIX) in renal
cell carcinoma patients [11], despite the relevant ‘‘on-target, off-
tumor’’ toxicity evidenced in the latter case. Lessons learned from
these experiences indicate that the definition of the target antigen
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for safety issues, and the persistence and tumor homing capacity of
infused cells are particularly critical for a successful treatment.
We addressed some of these questions by targeting prostate
tumor cancer cells with T cells modified to express a CAR specific
for the human prostate-specific membrane antigen (hPSMA).
Prostate tumor represents a serious clinical entity, with
estimated 233,000 new cases and 29,480 deaths in U.S. in 2014
[12], with at present only palliative treatments for hormone
refractory and metastatic forms [13]. For these patients, immu-
notherapy has proved to be a valid option based on vaccination
with modified whole prostatic tumor cells (GVAX [14]) or PBMC
presenting a relevant prostatic antigen (Sipuleucel-T [15]). With
regard to adoptive cell therapy approaches, preclinical studies
have reported encouraging results [13,16,17] and clinical evalu-
ation is undergoing (clinical trials number NCT01140373,
NCT01929239, NCT00664196; www.clinicaltrials.gov). In this
scenario, PSMA can represent a suitable target and indeed it is
currently exploited for both imaging and therapeutic purposes. In
particular, PSMA expression levels differentiate normal and
cancerous prostatic tissues, and parallel the Gleason score of
prostate cancer [18]. Interestingly, PSMA expression involves
neovasculature of several tumor entities, thus envisaging an
additional antiangiogenic effect.
Here, we report the design of CAR against hPSMA based on a
novel and high affinity specific mAb [19], and the phenotypic and
functional characterization of T-body-hPSMA both in vitro and
in vivo. For transduction, we used a lentiviral vector carrying a
bidirectional promoter which drives the simultaneous expression
of the CAR molecule and a reporter bioluminescent gene. This
allowed the tracking of infused T cells and hence the direct
correlation of the therapeutic outcome with the persistence and
homing capacity of T cells. Overall, CAR-transduced T cells not
only exerted a relevant loco-regional therapeutic activity, but also
completely eradicated a disseminated neoplasia in the majority of
treated animals. These results strongly support the translation of
such approach in the clinical setting.
Materials and Methods
Cell lines
The following cell lines were used in this study: LNCaP and
PC3, human prostate carcinoma cell lines; Jurkat, human T
lymphoblastic leukemia and 293 T [20], human embryonic kidney
cell line. The PC3-PIP cell line, stably expressing human PSMA
(hPSMA) [21] was generously provided by Dr. Warren Heston;
LNCaP cell line was obtained from American Type Culture
Collection (ATCC, Rockville, MD, USA). LNCaP, PC3, PC3-PIP
and Jurkat cells were maintained in RPMI 1640 medium
(EuroClone, Milan, Italy), while DMEM medium (Biochrom
AG, Berlin, Germany) was used for 293 T cells; both media were
supplemented with 10% Fetal Bovine Serum (FBS, Gibco BRL
Paisley, UK), 2 mM L-Glutamine, 10 mM HEPES, 100 U/ml
Penicillin, and 100 U/ml Streptomycin (all from Lonza, BioWhit-
taker, Basel, Switzerland), at 37uC in a 5% CO2 atmosphere.
Anti-hPSMA CAR generation
The CAR against the hPSMA antigen contains the complete
sequence of the anti-hPSMA scFv derived from the anti-hPSMA
D2B hybridoma [19]. This sequence was cloned into the multiple
cloning site (MCS) of the pSecTag2A vector (Invitrogen, San
Giuliano Milanese, Milan, Italy). The MCS of the pSecTag2A
plasmid is comprised between two sequences: in 59, the murine Ig
kappa light chain leader sequence V-J2-C, and in 39 the Myc Tag
sequence. Thus, the leader-ScFv-myc sequence was used for CAR
generation. The Leader-ScFv-myc fragment was amplified by
PCR and inserted in the pBS SKII construct (Invitrogen). A
portion of the CD28 (bases 438–759) and the CD3f intracellular
domain (227–563 region), both obtained from cDNA of EBV-
specific CD4+ T cells [22], were fused by PCR and then inserted
into the pBS SKII vector, downstream the Leader-ScFv-myc
fragment. This vector was then sequenced at the Centro Ricerca
Interdipartimentale Biotecnologie Innovative (CRIBI) of Padua
University, Italy. The anti-hPSMA CAR sequence was finally
subcloned into the pcDNA3.1 vector (Invitrogen). To check the
capacity to drive the expression of the CAR molecule on the
membrane, this vector was used to transfect 293 T cells by using
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s
instructions.
LV plasmids and lentiviral preparation
The following lentiviral packaging vectors were used: pMDLg/
pRRE, pRSV-Rev, pMD2.VSVG and pADVantage, all kindly
provided by Dr. L. Naldini (San Raffaele, Milan, Italy). The
transfer vector #945.pCCL.sin.cPPT.SV40ployA.eGFP.-
nCMV.hPGK.deltaLNGFR.Wpre is a self-inactivating (SIN)
HIV-derived vector [23], which carries a minCMVPGK divergent
bidirectional promoter driving the simultaneous expression of two
genes in antisense orientation. The transfer vectors used in this
study carried the anti-hPSMA CAR sequence (obtained from
pMA-T-body vector) under the control of the hPGK promoter,
and the eGFP (enhanced Green Fluorescent Protein) or Firefly
Luciferase (fluc) reporter genes under the control of minCMV.
pMA-T-body vector and fluc sequence were synthetized by
GeneArt, Life Technologies (Regensburg, Germany). Lentiviral
production in 293 T cells has been previously described [23]. A
lentiviral vector coding only for fluc [24] was used to transduce
PC3-PIP cells.
Western blot analysis
293 T cells, untransfected or transfected with pcDNA3.1-CAR,
were lysed in buffer containing 50 mM Tris HCl pH 6.8, 2%
sodium dodecyl sulfate (SDS), 2% b-Mercaptoethanol, 10%
glycerol, and 0.1–0.05% Bromophenol Blue (al from Sigma-
Aldrich, St. Louis, MO, USA) Proteins were separated on 10%
SDS-PAGE gels and transferred to PVDF membrane (Immobi-
lion-P, Millipore, Billerica, MA, USA). The membrane was
blocked in 5% skimmed milk (Sigma-Aldrich) in TBS and 0.05%
Tween 20, followed by incubation with the primary antibody
(mouse anti-c-Myc mAb, 1:1000, Sigma-Aldrich) for one hour at
room temperature. After three 10-minutes washes in PBS-Tween,
HRP-conjugated goat anti-mouse IgG secondary antibody (diluted
1:10000, Amersham, Milan, Italy) was added for one hour at room
temperature in milk. The membrane was developed using the
SuperSignal West Pico (Pierce, Rockford, IL, USA) and visualized
using chemiluminescence. Signal intensity was measured using a
Bio-Rad XRS chemiluminescence detection system (Life Science
Group, Milan, Italy).
Jurkat cell transduction
To assess the functionality of LV vectors, Jurkat cells were
incubated with viral supernatant (hPSMA/eGFP LV CAR or
hPSMA/Luciferase LV CAR) for 15 hours in the presence of
8 mg/ml protamine sulfate (Sigma-Aldrich). Flow cytometry and
Bioluminescence (BLI) analyses were carried out at different time
points post transduction to evaluate CAR and eGFP expression or
luciferase activity.
CAR-T Cells for Prostate Cancer
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T-bodies generation
To generate T-bodies, PBMC from healthy donors were
activated 48 hours with OKT-3 (50 ng/ml; Ortho Biotech Inc,
Raritan, NJ, USA) and human IL-2 (hIL-2, 300 U/ml; Proleukin;
Novartis Pharmaceuticals, Horsham, UK). T cells were then
infected with the viral supernatant for 18 hours at 37uC and 5%
CO2, in the presence of protamine sulfate (40 mg/ml; Sigma-
Aldrich) and hIL-2 (500 U/ml). The supernatant was then
changed with fresh complete medium containing hIL-2 (100 U/
ml). Seventy-two hours later, PBMC were analyzed for CAR and
eGFP expression, and for luciferase activity. PBMC were referred
to as T-body-hPSMA/eGFP and T-body-hPSMA/fluc when
transduced with hPSMA/eGFP LV CAR or hPSMA/Luciferase
LV CAR, respectively. T-bodies were re-stimulated once a week
with irradiated (60 Gy) PC3-PIP at a 10:1 ratio. Complete
medium with fresh IL-2 was replenished twice a week.
Antibodies
CAR-expressing cells were labeled with the anti-c-myc mAb
(clone 9E10; Sigma-Aldrich) or the isotype control (mouse IgG1,
Southern Biotech, Milan, Italy), followed by a secondary antibody
(PE-conjugated goat anti-mouse IgG; Southern Biotech). Cell
surface markers were labeled using APC-, FITC- or PE-
conjugated antibodies to CD4, CD8, CD57, CD27, CD28,
CD62L (BioLegend, San Diego, CA, USA), CCR7 (eBioscience,
San Diego, CA, USA), and the relative isotype controls purchased
from the same companies.
Cytotoxicity assay
The cytotoxic activity of T-body-hPSMA/eGFP and T-body-
hPSMA/fluc was assessed in a standard 4 h 51Cr-release assay as
previously reported [25], at different time points post-transduc-
tion. PC3, PC3-PIP and LNCaP were used as target cells.
Cytokine release assays
To evaluate IFN-c production, an ELISA IFN-c Screening Set
(Thermo Scientific, Rockford, IL, USA) was used, according to
manufacturer’s instructions. Briefly, 16106 T cells were seeded
with 16106 target cells (PC3 or PC3-PIP) in triplicate wells in 96-
well round bottom plates. Cytokine secretion was measured after
12 hours of incubation using T-bodies at different stages of
differentiation. Negative and positive controls were represented by
untransduced PBMC and T-bodies unstimulated or treated with
40 ng/ml of PMA and 4 mg/ml of Ionomycin (Sigma-Aldrich),
respectively. Supernatants were then analysed on a VICTOR X4
(PerkinElmer, Zaventem, Belgium).
Mice and in vivo experiments
In vivo experiments involved 6 to 8 week-old males SCID,
Rag22/2/cc2/2 and NOD/SCID mice (Charles River Labora-
tories, Calco, Como, Italy), which were housed in the specific
pathogen-free animal facility of the Department of Surgery,
Oncology and Gastroenterology, Padua University (Italy). Animals
were housed with a 12- hour light/dark cycle, in temperature
(22+/21uC) and humidity (55+/25%) controlled room. All mice
were allowed free access to water and a maintenance diet. All
cages housed up to 6 animals and contained wood shavings and a
cardboard tube for environmental enrichment. Procedures
involving animals and their care were in conformity with
institutional guidelines that comply with national and international
laws and policies (D.L. 116/92 and subsequent implementing
circulars), and the experimental protocol (nu7/2012) was approved
by the local Ethical Committee of Padua University (CEASA).
During in vivo experiments, animals in all experimental groups
were examined daily for a decrease in physical activity and other
signs of disease; severely ill animals (weight loss exceeding 15%,
lethargy, ruffled hair, low temperature) were euthanized by carbon
dioxide overdose.
Winn assay. Winn assay was performed by injecting s.c.
SCID mice with 56106 PC3 or PC3-PIP tumor cells per animal,
mixed with either RPMI or T-body-hPSMA/eGFP cells (56106/
mouse; 6 mice/group). Tumor volume was calculated according to
the following equation: V (mm3) = (d2 * D)/2, where d (mm) and D
(mm) are the smallest and largest perpendicular tumor diameters,
respectively, as assessed by caliper measurement.
Loco-regional treatment. To evaluate the therapeutic
potential of the loco-regional treatment, SCID mice were injected
s.c. with 56106 PC3-PIP cells. When tumors become palpable
about four days later, mice were randomly assigned to the control
group (they were left untreated) or the experimental group (they
were injected intralesionally with CAR-transduced T cells at 72
hours after transduction; 6 mice/group). Two primary outcomes
were analyzed: tumor growth was monitored over time by caliper
measurement and the overall survival was recorded.
Systemic treatment of subcutaneous prostate
tumors. To assess the therapeutic activity of the systemic T-
body administration, SCID mice were injected s.c. with 56106
PC3-PIP cells and 4 days later they received i.v. T-body-hPSMA/
fluc (106106/mouse) at 72 hours or 5–6 weeks post transduction
(n= 6); untreated animals served as control group (n= 6). T cell
biodistribution was assessed by bioluminescence imaging (BLI) in
the same conditions, except that mice were injected with both
PC3-PIP or PC3 tumor cells on the right and left flank,
respectively.
Disseminated prostatic tumor model. To set up a model
of disseminated prostatic tumor, SCID, Rag22/2/cc2/2 and
NOD/SCID mice were injected i.v. with different numbers
(ranging from 16105 to 56106) of fluc-transduced PC3-PIP cells (6
mice/group). Tumor engraftment and growth were evaluated by
BLI. Moreover, tumor-free SCID, Rag22/2/cc2/2 and NOD/
SCID mice were injected with 206106 T-body-hPSMA/fluc, to
evaluate their fate by BLI (6 mice/group).
Adoptive immunotherapy experiments. In adoptive im-
munotherapy experiments, bioluminescent PC3-PIP were injected
i.v. in NOD/SCID and Rag22/2/cc2/2 mice (16105/mouse).
Four days later, animals were randomly assigned to the control
group (they were left untreated) or the experimental group, where
they received i.v. 206106 T-body-hPSMA/eGFP for 3 times
within a week (6 mice/group). Tumor growth was monitored
weekly by BLI, and survival was recorded.
Quantitative Bioluminescence
Quantitative BLI is a powerful technology that allows to obtain
multiple images longitudinally and, at the same time, to reduce
animal numbers. Bioluminescence images were collected with the
IVIS Lumina II Imaging System (PerkinElmer). Ten to 15 min-
utes before imaging, animals were anesthetized with isoflurane/
oxygen and administered i.p. with 150 mg/kg of D-luciferin
(PerkinElmer) in PBS. Three mice were imaged simultaneously
with exposure times ranging from 0.5 to 3 min. A 12612 cm field
of view and low, medium, or high binning levels were applied to
maximize sensitivity and spatial resolution. Ventral images were
obtained for each animal and quantified through the region of
interest (ROI). Living Image Software (PerkinElmer) was used to
acquire and quantify the bioluminescence imaging data sets.
CAR-T Cells for Prostate Cancer
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Cytofluorimetric evaluation of hPSMA expression in
growing tumors
Tumor cells suspensions were obtained by enzymatic digestion
with 270 units/ml DNase, 35 U/ml hyaluronidase, and 200 U/
ml collagenase buffer (all from Sigma-Aldrich). After a 30-min
incubation at 37uC, the cells were passed through a 70-mm cell
strainer (BD Biosciences, San Jose, CA, USA). Samples were then
stained at 4uC with a mouse anti-hPSMA mAb [19] followed by a
PE-conjugated anti-mouse IgG1 secondary antibody (BioLegend)
and analyzed on a FACSCalibur (BD) flow cytometer. Data were
evaluated with FlowJo software (TreeStar Inc., Olten, Switzer-
land).
Statistical analysis
Kaplan–Meier product-limit method was performed to estimate
the survival curves, and comparison of survival between groups
was performed using the log-rank test. Statistical analyses were
carried out with the Sigmaplot (version 12.3) statistical package.
Results
Construction and development of an efficient
bidirectional LV for anti-hPSMA CAR expression
A CAR sequence was designed that encoded the following
components in-frame from 59 to the 39 ends (Fig. 1A): a leader
sequence, the single-chain variable fragment (ScFv) of the new
anti-hPSMA antibody IgGD2B [19], the c-myc tag sequence, and
the CD28 costimulatory molecule linked to the CD3f sequence.
We decided to exploit this new anti-PSMA scFv (scFvD2B) for the
construction of our CAR, because of its very appealing charac-
teristics, in particular the nanomolar affinity for the target that is
similar to the one evidenced by the whole J591 antibody [19].
Moreover, our scFvD2B shows high specificity and identifies a
different epitope from that recognized by the J591 antibody, as
assessed by competition experiments carried out with radio-
immunoligands or biotin-labeled antibodies ([19] and data not
shown).
To assess the capacity of the construct to drive the expression of
a receptor that correctly mounted on the cell membrane, the anti-
hPSMA CAR sequence was cloned into the pcDNA3.1 vector and
the resulting plasmid was used for transient transfection of 293 T
cells. At different time points thereafter, the expression of the
chimeric receptor was assessed by cytofluorimetric and Western
blotting analysis (Fig. 1B and 1C, respectively), using the anti-c-
myc mAb. Results disclosed that the CAR was correctly mounted
on the membrane and had the expected molecular weight (about
60 kDa); CAR expression was already detectable 24 hours post-
transfection, to rapidly disappear the next days due to the lack of a
selection step (Fig. 1C). Subsequently, the CAR sequence was
inserted into a LV carrying a bidirectional promoter that allowed
transcription of a reporter gene (eGFP or fluc) from the upstream
minimal promoter minCMV, without affecting downstream
expression of the anti-hPSMA CAR from the efficient hPGK
promoter (Fig. 1D). To assess functionality of the lentiviral vectors,
Jurkat cells were transduced with LV CAR hPSMA/eGFP and
LV CAR hPSMA/fluc. CAR turned out to be highly expressed
already 72 hours post-transduction, as demonstrated by the high
percentage of c-myc+ cells detected by flow cytometry analysis
(Fig. 1E and 1F). In particular, CAR-expressing cells were more
than 90% when transduced with LV CAR hPSMA/eGFP
(Fig. 1E) and more than 60% when using LV CAR hPSMA/
fluc (Fig. 1F, left panel). Notably, the bidirectional LV vectors
appeared to drive the expression of either the CAR and the
reporter genes with a very balanced efficiency, as demonstrated by
the high intensity of eGFP signal (Fig. 1E) and the relevant
Luciferase activity (Fig. 1F, right panel).
Phenotypic characterization of CAR-transduced T cell
populations
For the generation of T cell populations expressing the anti-
hPSMA CAR, a rapid expansion protocol was developed. The
optimal infection time was set up after 48 hours of OKT3
activation, since at this time point we obtained the highest
percentage of CAR-expressing T cells (Fig. 2A, left panel), and a
less differentiated phenotype, as assessed by the high expression of
CD27, CD28 and CD62L markers (Fig. 2A, central panel).
Subsequently, the expansion protocol involved weekly restimula-
tion with PC3-PIP cells that allowed a rapid and sustained
proliferation of both T-body-hPSMA/eGFP and T-body-
hPSMA/fluc populations (Fig. 2A, right panel).
To better define the state of differentiation of CAR-transduced
T lymphocytes in the post infection period during antigenic
restimulations, expression of different surface markers (CD62L,
CD27, CD28, CCR7, CD57) was assessed by cytofluorimetric
analysis. Seventy-two hours after transduction, the emerging
profile was essentially of early effector T cells, as shown by the
high expression of CD62L, CD27 and CD28, the presence of
CCR7 positive cells and the low expression of CD57 (Fig. 2B, left
panel). Following restimulations with the antigen, T cells acquired
an intermediate effector memory phenotype with the progressive
down-modulation of CD62L, CD28 and CCR7 and a slight
increase in CD57 expression (Fig. 2B, left panel). Interestingly,
whereas the subsequent encounter with the antigen led to the
expansion of the CAR-expressing population (Fig. 2B, right
panel), a dichotomy could be observed between the expanding T
cell subsets. Indeed, while CAR expression was almost equal
within the CD4+ and CD8+ T cell populations immediately after
infection, the antigenic restimulation determined the progressive
accumulation of the CD8+ T cell subset only, which almost
completely overcame CD4+ T cells by month one after
transduction (Fig. 2C).
Functional characterization of CAR-expressing T cells
CAR expression provided the transduced population with the
ability to recognize the hPSMA antigen on the surface of prostate
tumor cell lines, and to mediate a high and specific cytotoxicity
(Fig. 3A). Indeed, both the T-body-hPSMA/fluc and T-body-
hPSMA/eGFP populations lysed the hPSMA-transfected PC3
cells while sparing the antigen-negative counterpart; more
importantly, they were also capable of recognizing the LNCaP
target cells that naturally harbour the hPSMA antigen. Cytotox-
icity was already evident, albeit at low levels, 3 days after
transduction and increased at maximal levels just after a single
round of antigen restimulation, to remain constant thereafter up to
2 months post-infection. Other than exerting a relevant cytotoxic
activity, CAR-transduced T cells at different stages of differenti-
ation also produced high levels of IFN-c in response to hPSMA-
expressing tumor cells (Fig. 3B and 3C), but not against hPSMA
negative control cells. As a negative control, uninfected T cells did
not produce IFN-c when co-cultured with PC3 cells engineered to
express the surface hPSMA antigen.
Analysis of therapeutic efficacy of anti-hPSMA T-body
administration against local prostate tumors
In vivo therapeutic efficacy of CAR-transduced T cells at
different stages of differentiation (72 hours or 5 weeks post-
transduction) was initially evaluated using a Winn assay (Fig. 4A).
CAR-T Cells for Prostate Cancer
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Figure 1. CAR development and validation. (A) Anti-hPSMA CAR map. EC: extracellular domain; TM: transmembrane domain; IC: intracellular
domain. (B) Cytofluorimetric profile of CAR expression in transfected 293 T cells. 293 T cells were transfected with pcDNA3.1 vector bearing CAR
sequence and analysed by flow cytometry after 24 hours (dark line). Untransfected cells (grey plot) served as control. (C) CAR expression as assessed
by Western blotting at 24 hours (line 1) and 7 days (line 2) post 293 T cell transfection. Negative controls were the medium alone (line 3) and
untransfected 293 T cells (line 4). Line 5, molecular weight markers. (D) Linear map of the recombinant viral vector containing the minCMVPGK
bidirectional promoter (22). In particular, the reporter gene (eGFP or Luciferase) is under the control of minCMV promoter, while the CAR gene is
under control of hPGK promoter. (E) Transduction of Jurkat cells with LV CAR anti-hPSMA/eGFP. Co-expression of c-myc and eGFP in LV-transduced
Jurkat cells, as assessed by flow cytometry. Dot plot reports the events gated on total viable cells; more than 90% of cells co-express both c-myc and
eGFP. (F) Transduction of Jurkat cells with LV CAR anti-hPSMA/Luciferase. Left panel, c-myc expression (black) in Jurkat cells at 72 h post transduction,
as assessed by flow cytometry. Grey plot represents the isotype control. Right panel, Assessment of luciferase activity in LV-transduced Jurkat cells
(26105/well) by BLI.
doi:10.1371/journal.pone.0109427.g001
CAR-T Cells for Prostate Cancer
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e109427
In particular, when PC3-PIP tumor cells were co-injected with T-
body-hPSMA/eGFP no tumor growth was observed (Fig. 4A, left
panel), irrespective of the differentiation stage of T-bodies. On the
other hand, T cell transfer did not significantly impact the growth
of hPSMA-negative PC3 tumor cells (Fig. 4A, right panel).
Since the Winn assay does not recapitulate a real therapeutic
setting, we assessed the antineoplastic activity of CAR-transduced
Figure 2. Generation, expansion and phenotipic properties of T-bodies. (A) Set up of transduction protocol and growth kinetics. Left panel,
PBMC were activated with OKT3 at time 0 and transduced concomitantly (Td0), or after 48-h (Td2) or 72-h (Td3) hours. Flow cytometry analysis of c-
myc tag expression was performed 72 hours post infection. Central panel reports the expression of CD27, CD28 and CD62L in the three different
conditions of activation/infection reported in the left panel. Right panel, Expansion of T-body-hPSMA/fluc and T-body-hPSMA/eGFP transduced after
48 h activation in response to weekly restimulation with PC3-PIP cells. Untransduced PBMC were used as control. (B) Phenotype and CAR expression
in transduced T cells upon stimulation. Left panel, Expression of surface markers in T-body-anti-hPSMA/fluc at different time points (3, 11 and 18 days)
post transduction, as assessed by flow cytometry. Data are representative of 3 independent experiments. Overlapping results were obtained in T-
body-anti-hPSMA/eGFP. Right panel, percentage of c-myc+ cells in LV CAR hPSMA/fluc and LV CAR hPSMA/eGFP-transduced T cell populations at
different time points post transduction. Figure shows mean +/2 SD of at least three independent experiments. (C) Kinetics of CD4 and CD8 subsets in
transduced T cell populations. Expression of CD4 and CD8 markers in c-myc+-gated T-body-hPSMA/eGFP (left panel) and T-body-hPSMA/fluc (right
panel) populations at different time points post transduction, as assessed by flow cytometry. Data are from a representative experiment out of three
that produced similar results.
doi:10.1371/journal.pone.0109427.g002
CAR-T Cells for Prostate Cancer
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T cells against established tumors. SCID mice were injected s.c.
with PC3-PIP cells and, when tumors became palpable, they
received intratumorally and peritumorally T-body-hPSMA/eGFP
at 72 hours post-transduction. While progressive tumor growth
was observed in untreated control mice, treated masses shrank up
to almost disappear, at least for the first week after treatment
(Fig. 4B, left panel). Thereafter, tumors resumed to grow in 3 out
of 6 treated mice, even though with a strong delay and a slower
kinetics (Fig. 4B, left panel). Nevertheless, a single injection of
CAR-transduced T cells produced a complete regression of the
tumor in 50% of treated animals (3/6) and a statistically significant
increase in survival (p = 0.0028; Fig. 4B, right panel).
To assess if the resumption of tumor growth could be due to the
emergence of antigen-loss escape variants induced by the selective
pressure of the immunological treatment, we analyzed the
expression of hPSMA on tumor cells recovered ex vivo from
treated and untreated mice (Fig. 4C). Indeed, this hypothesis could
be ruled out because ex vivo cancer cells from both treated and
control mice displayed overlapping profiles of hPSMA expression.
Nonetheless, these expression levels turned out to be strongly
reduced respect to the cultured tumor cells, as evidenced by a one-
log decrease in the fluorescence intensity signal.
Finally, T-body-hPSMA/fluc were administered systemically to
mice bearing s.c. tumors, but did not display therapeutic activity
(Fig. S1A). This failure was very likely due to the poor capacity of
infused T cells to reach the tumor site (Fig. S1B). Such result is in
line with previous data obtained by our group in a different
experimental setting, which involved the i.v. administration of
Melan-A/MART-1-specific TCR-transduced T cells in mice
bearing established s.c. melanoma tumors [20].
Assessment of therapeutic efficacy of anti-hPSMA T-body
administration against disseminated prostate tumors
While the loco-regional approach provided evidence of efficacy
and specificity, a systemic treatment against a disseminated
prostate tumor model would better resemble the clinical setting.
To this end, different numbers of PC3-PIP cells were injected i.v.
in SCID mice and tracked for their persistence and biodistribution
by BLI; unexpectedly, they apparently disappeared very rapidly
and failed to form detectable tumor masses up to one month after
injection (Fig. S2 and data not shown). Therefore, tumor growth
was then tested in two more immunocompromised animal strains,
namely Rag22/2/cc2/2 and NOD/SCID mice. In such strains,
tumor cells disseminated and displayed a sustained growth as soon
as 7–14 days after injection, even when administered at low
amounts (Fig. S2).
As a complimentary approach, biodistribution and persistence
of i.v.-administered T-body-hPSMA/fluc was also tested in
healthy individuals of these mouse strains. In SCID mice, T cells
disappeared just few hours after injection; conversely, T cell
survival appeared slightly increased in Rag22/2/cc2/2 mice,
although the BLI signal was detectable only in the lungs; on the
other hand, bioluminescence in NOD/SCID mice distributed
uniformly throughout the body and could be tracked up to
seventy-two hours (Fig. S3 and data not shown). Based on this
evidence, we assessed the systemic therapeutic efficacy of T-bodies
in Rag22/2/cc2/2 and NOD/SCID mice (Fig. 5). Animals were
injected i.v. with bioluminescent PC3-PIP cells and treated with
26107 T-body-hPSMA/eGFP for 3 times at 2 day intervals. In
both mouse strains, this ACT approach strikingly reduced the BLI
signal in lungs of treated animals as compared to control mice
(Fig. 5A and 5B). Notably, while in Rag22/2/cc2/2 mice
Figure 3. Functional characterization of T-bodies. (A) Lytic activity of T-body-hPSMA/eGFP and T-body-hPSMA/fluc. Cytotoxicity was analysed
at 3, 11 and 60 days post-transduction; PC3, PC3-PIP and LNCaP cells were used as target cells. Untransduced PBMC served as negative control. In the
upper left corner of each panel the percentages of c-myc+ T cells are reported. Figure shows mean +/2 SD of 4 independent experiments. (B) IFN-c
secretion upon antigen stimulation. IFN-c production was analyzed at different time points after PBMC transduction by stimulating T-body-hPSMA/
fluc with PC3-PIP hPSMA+ or PC3 hPSMA2 cancer cell lines. T-bodies unstimulated or treated with PMA/Ionomycin represented the negative and
positive controls, respectively. Similar results were obtained with T-body-hPSMA/eGFP. (C) c-myc expression in T-body-hPSMA/fluc populations
tested for IFN-c production.
doi:10.1371/journal.pone.0109427.g003
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bioluminescent lesions involving extra-pulmonary sites ultimately
appeared, no metastatic disease become apparently evident in
NOD/SCID mice (Fig. 5A and 5C), likely due to the total body
diffusion of transferred T-bodies (Fig. S3). These results reflected
on the long-term survival of treated mice (Fig. 5D). Indeed, the
transfer of CAR-transduced T cells significantly improved survival
in both strains of mice; more importantly, the treatment afforded
to completely eradicate the neoplasia in more than 60% of NOD/
SCID animals (4/6), which were completely disease-free 150 days
after tumor induction.
Discussion
The high curative potential against hematologic malignancies
afforded by CAR T cells support the large number of clinical trials
targeting these entities (36 out of 62 trials retrieved at www.
clinicaltrials.gov by using the following key words: ‘‘Chimeric
Antigen Receptor’’, ‘‘CAR’’, ‘‘T-Body’’ and ‘‘Designer T cells’’),
and in particular those expressing the CD19 antigen (29/36).
Conversely, the difficulties intrinsic to the treatment of solid
tumors (in particular the choice of suitable and safe target antigens)
and the largely unsatisfactory results obtained thus far make them
a less appealing but still open field of battle for immunotherapeutic
strategies.
Here, we propose a second generation anti-hPSMA CAR based
on a novel and high affinity scFv [19], and provide evidence of a
strong and specific antitumor activity by the resulting T-bodies-
hPSMA against a prostate tumor model, not only in vitro but also
in vivo; in particular, we completely eradicated a disseminated
Figure 4. Assessment of T-body in vivo loco-regional therapeutic efficacy. (A) Winn Assay. PC3-PIP (left panel) and PC3 (right panel) tumor
cells were inoculated s.c. in SCID mice, alone or mixed 1:1 with T-body-hPSMA/eGFP at opposite flanks of the same animal. Tumor growth was
monitored over time by caliper measurement. Number of mice per group, n = 6. (B) Loco-regional therapy. T-body-hPSMA/eGFP at 72 hours post
transduction were administered intralesionally and perilesionally in SCID mice 4 days after s.c. injection of PC3-PIP tumor cells (n = 6); untreated
animals served as control group (n = 6). Left panel shows tumor volumes, while right panel reports Kaplan-Meyer survival curves of treated and
untreated mice. (C) Expression of hPSMA antigen in prostate tumors. PC3-PIP tumor cells from in vitro cultures (first quadrant) or isolated ex-vivo from
control or treated mice (second and third quadrant, respectively; dark line) were evaluated for hPSMA expression by flow cytometry. The grey plot
corresponds to the isotype control.
doi:10.1371/journal.pone.0109427.g004
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neoplasia in more than 60% of treated NOD/SCID animals. This
experimental design appears to recapitulate more realistically a
clinical situation than the systemic treatment of localized tumors
(s.c. tumors or pulmonary metastatic models [13,16,17,26]);
indeed, while the efficacy of our approach against localized
tumors may appear reduced in comparison to other reported
models [13,16,26], results of our systemic treatment against
disseminated neoplasia reproduce or even outperform previously
published data. As an example, the infusion of 3rd generation anti-
PSCA CAR-transduced T cells induced only a tumor growth
delay, albeit statistically significant [16].
Interestingly, the therapeutic superiority of 3rd over 2nd
generation CAR is far from being undoubtedly demonstrated.
Conflicting evidences came from pre-clinical studies [17,27], and
only a pilot clinical trial involving 3rd generation CAR against
CD20+ B-cell malignancies has been published thus far [28]. In
fact, no definitive conclusions can be drawn because of the low
number of enrolled patients and the very low CAR expression
obtained through plasmid electroporation (below the limit of
detection by flow cytometry and Western blotting), which
precludes the realistic assessment of potential adverse events. This
safety aspect acquires even more importance in the case of the
addition of the 4-1BB moiety, which can induce not only antigen-
dependent but also antigen-independent proliferation [29], thus
carrying additional risks of cell-mediated acute toxicity. Moreover,
an excess of stimulation can be detrimental to modified cells, due
to the potential induction of activation-induced cell death (AICD),
as demonstrated for 3rd generation CAR-transduced CIK cells
[30].
On the other hand, 3rd generation CAR appeared to prolong T
cell survival at least in preclinical models [17,26]. In a clinical
setting, this issue will be addressed by the side-by-side comparison
between 3rd and 2nd generation CAR-T cells in a currently
recruiting clinical trial (SAGAN, NCT01853631), as previously
assessed for the 2nd and 1st generation CAR-T cells [31].
Nonetheless, in our hands a second generation CAR design
appeared to deliver very balanced activation/costimulatory
signals, which were sufficient to sustain the in vivo persistence of
T cells at detectable levels until the therapeutic activity became
evident. This result was achieved despite the fact that our T-bodies
displayed a sub-optimal effector phenotype at the time of transfer
and did not receive any additional help. Indeed, they operated
without exogenous IL-2 supply and in the virtual absence of CD4+
T cells (,5%). In this regard, it is noteworthy that the percentage
of CD4+ T cells appeared to positively correlate with the clinical
outcome in neuroblastoma patients treated with GD2-CAR
specific T cells [8], and other protocols comprise the addition of
unmodified CD4+ T cells to the infusates [27].
Moreover, the elevated and sustained expression of high affinity
CAR molecules likely concurred to the outcome, leading to
compensate for the reduced PSMA expression on target cells
in vivo. A down-modulation of Ag expression is not an unexpected
circumstance for human cell lines upon in vivo transfer in a mouse
host [32,33]. Accordingly, a reduced Ag expression can potentially
jeopardize the final outcome, since the intensity of Ag expression
has been correlated with the kinetic of killing performed by CAR-
T cells, and ultimately with their capacity to completely eradicate
a tumor [34].
The transgene expression level was achieved by means of a
lentiviral vector with a very efficient bidirectional promoter [23].
This same lentiviral vector, albeit carrying a different CAR
molecule, performed equally well compared to a related retroviral
construct [35] in terms of transgene expression levels and
antitumor activity. In addition, a lentiviral vector was chosen
instead of the more widely used retroviral constructs because of
technical considerations (less significant gene expression silencing
due to position effects [29]), and the safety profile. Indeed, the use
of retroviral vectors can be afflicted by a considerable risk of
leukemogenesis, as recently demonstrated in a clinical trial for
Wiscott-Aldrich Syndrome [36]. The follow-up for clinical use of
lentiviral vectors is at present too short to completely exclude
genotoxicity, but data from experimental models, which were
predictive for retroviral vectors, come out in favor of a less
pronounced risk of insertional mutagenesis [37,38].
Thanks to the bidirectional promoter, the lentiviral vector used
allowed the simultaneous expression of the CAR and a reporter
gene, and hence the visualization of T cells after transfer; thus, we
could positively correlate the persistence and the total body
diffusion of T cells with their therapeutic efficacy. Indeed, whereas
transferred T cells were detected only in the lungs of Rag22/2/
cc2/2 mice, they disseminated uniformly throughout the body
and persisted longer in the NOD/SCID strain. Accordingly,
treated Rag22/2/cc2/2 mice developed tumor masses in extra-
pulmonary sites and ultimately died, while more than 60% of
NOD/SCID mice were still alive 150 days after tumor induction
and showed no metastatic disease at sacrifice.
Two main questions remain that cannot be adequately assessed
per se by a xenogeneic model, i.e. the validation of the chosen
target and the related risk of ‘‘on-target, off-site’’ toxicity [39].
Indeed, preclinical models did not predict the dramatic events that
occurred after translation in clinical trials [40,41]. In this regard,
PSMA is physiologically expressed in kidney, nervous system glia,
and small intestine [18], and the risk to damage these organs and
structures cannot be excluded simply based on the fine target
specificity demonstrated in an experimental setting by the novel
mAb we used to design our CAR [19]. However, in a clinical
scenario, this vector containing a bidirectional promoter could be
exploited to address this safety issue, namely by driving the
simultaneous expression of a CAR molecule and a ‘‘safety switch’’
suicide gene, such as an inducible caspase or the herpes simplex
virus thymidine kinase (HSV-TK) [35,42]; or alternatively a
chimeric costimulatory receptor (CCR) for combinatorial antigen
recognition [43].
In conclusion, the novel CAR developed can be envisaged as a
potential new weapon in the arsenal against prostate tumor and
reported data strongly support its clinical exploitation based on the
potent in vivo anticancer activity.
Figure 5. Assessment of T-body in vivo systemic therapeutic efficacy against disseminated prostate carcinoma. Rag22/2/cc2/2 mice
(n = 6) and NOD/SCID mice (n = 6) bearing established bioluminescent PC3-PIP tumors were injected i.v. with 26107 T-body-hPSMA/eGFP for 3 times
at a two day interval. Untreated animals (n = 6 for both mouse strains) were used as controls. (A) Pictures show two representative Rag22/2/cc2/2
and NOD/SCID mice (left and right panels, respectively) imaged by BLI at different time points, whereas (B) and (C) graphs report cumulative results of
the regions of interest (ROI) in lungs and in total body, respectively. Tumor growth was monitored as photon flux and quantified as photon * sec21 *
cm22 * sr21. Graphs show mean 6 SD of three independent experiments. *: P,0.05. The t-Test was used for statistical analysis. (D) Cumulative
Kaplan-Meier survival curves of Rag22/2/cc2/2 (left panel; untreated mice, black line; median survival = 54 days; treated mice, red line; median
survival = 74 days; P = 0.046) and NOD/SCID mice (right panel; untreated mice, black line; median survival = 60 days; treated mice, red line; median
survival = not evaluable; P,0.001).
doi:10.1371/journal.pone.0109427.g005
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Supporting Information
Figure S1 Assessment of therapeutic efficacy of i.v.-
administered T-bodies against subcutaneous prostate
tumors. (A) T-body-hPSMA/fluc at 72 hours or 5–6 weeks post
transduction were administered i.v. in SCID mice 4 days after s.c.
injection of PC3-PIP tumor cells (n = 6); untreated animals served
as control group (n= 6). (B) T-bodies-hPSMA/fluc were inoculat-
ed i.v. in SCID mice 4 days after s.c. injection of PC3-PIP (right
flank) or PC3 (left flank) tumor cells; cell distribution was assessed
at different time points thereafter. Two representative mice out of
six are depicted.
(TIF)
Figure S2 Set up of a disseminated prostatic tumor
model. Comparison of tumor growth in SCID (upper panels),
Rag22/2/cc2/2 (central panels) and NOD/SCID (lower panels)
mouse strains. Different numbers of bioluminescent PC3-PIP cells
were injected i.v., and their survival and distribution were assessed
at different time points. Images of two representative mice for each
group are shown.
(TIF)
Figure S3 T-bodies biodistribution in healthy mice of
different strains. T-bodies-hPSMA/fluc (206106/mouse) were
inoculated i.v. in SCID (left panels), Rag22/2/cc2/2 (central
panels) and NOD/SCID (right panels) mice; cell distribution and
survival was assessed at different time points thereafter. A
representative mouse for each group is depicted.
(TIF)
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